https://drugdiscoveryscreening....s.com/index.php/tran
Baseline attributes, mutation profile, and results had been compared between customers with regular cytogenetics(NC) and people with IC. Sixty-one patients (males 39.3%; median age 59 years) had IC at diagnosis. The proportion of patients with mutations in genes with proven prognostic impact weren't different between AML patients with IC and NC. AML patients with NC had been very likely to harbor the prognostically favorable NPM1 mutational combina
Like
Comment
Share
